Form 4: Tenaya Therapeutics Director Receives Significant Stock Option Grant

Karah Herdman Parschauer, a Director at Tenaya Therapeutics, Inc., has been granted 107,400 stock options with an exercise price of $0.4444 per share, vesting over one year.

Summary

• Karah Herdman Parschauer, a Director of Tenaya Therapeutics, Inc. (TNYA), was granted 107,400 stock options.
• The options have an exercise price of $0.4444 per share.
• The grant occurred on May 29, 2025, under the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan.
• These options are scheduled to vest in full on May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date.
• Vesting is contingent upon Ms. Parschauer continuing to serve as a service provider to the Issuer through the applicable vesting date.
• The options have an expiration date of May 28, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine stock option grant to a director, which is a positive for aligning interests but does not indicate significant new financial performance or strategic shifts. It's a standard compensation disclosure.

Positives

• The grant of stock options to a director helps align their financial interests with those of the shareholders, incentivizing long-term performance and value creation for Tenaya Therapeutics.
• The transaction is part of the company's established 2021 Equity Incentive Plan, indicating a structured and approved approach to director compensation.

Negatives

• The exercise of these options in the future could lead to a degree of share dilution, as new common stock would be issued.

Risks

• The vesting of the granted stock options is subject to the reporting person's continued service to Tenaya Therapeutics, Inc. through the specified vesting date; failure to meet this condition could result in forfeiture of the unvested options.
• The ultimate value of the stock options is dependent on the future market price of Tenaya Therapeutics, Inc. common stock exceeding the exercise price of $0.4444 per share.

Future Outlook

The stock option grant provides a long-term incentive for the director, aligning their future financial interests with the company's performance and shareholder value creation, contingent on continued service.

Industry Context

The granting of stock options to directors is a standard practice within the biotechnology and pharmaceutical industries, serving as a common form of equity compensation to attract, retain, and incentivize key personnel.

Comparison to Industry Standards

• Granting stock options as a form of equity compensation to directors is a common practice across the biotechnology and pharmaceutical industries, aligning director incentives with shareholder value.
• The structure, including vesting periods and an exercise price, is typical for such grants, aiming to retain talent and encourage long-term commitment.

Corporate Governance

Related Party Transactions

• The grant of 107,400 stock options to Karah Herdman Parschauer, a Director of Tenaya Therapeutics, Inc., constitutes a related party transaction as it involves a transaction between the company and an insider.

Stakeholder Impact

• Shareholders: Potential for future dilution upon option exercise, but also benefit from aligned director incentives for long-term company performance.
• Director (Karah Herdman Parschauer): Receives equity compensation that ties her financial reward to the company's stock performance and continued service.

Next Steps

• The granted stock options will vest in full on May 29, 2026, or earlier, subject to the director's continued service.
• Upon vesting, the director will have the right to exercise the options to acquire common stock at the specified exercise price.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, SEC Form 4, Stock Option Grant, Director Compensation, Equity Incentive Plan, Insider Transaction, Beneficial Ownership